Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Ifosfamide IP 1gm Injection
Therapeutic Category
Oncology, Anticancer
Dosage Form
Injection
Packaging Type
Vial
Packaging
1gm
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
IFOSIDE 1GM Injection (Ifosfamide IP 1 gm) is a potent alkylating antineoplastic agent widely used as a cornerstone in combination chemotherapy protocols for advanced and recurrent cancers. As a prodrug, Ifosfamide is metabolically activated in the liver by CYP450 enzymes into active metabolites (primarily isophosphoramide mustard) that form highly damaging DNA cross-links. This mechanism effectively inhibits DNA synthesis and repair, leading to cancer cell death.
Key Clinical Applications:
Testicular Germ Cell Tumors: Indicated specifically as a third-line chemotherapy agent.
Sarcomas: A vital component in treating Soft Tissue Sarcoma and Osteosarcoma (bone cancer).
Lymphomas and Others: Used in regimens for Non-Hodgkin's Lymphoma and certain refractory cases of Small Cell Lung Cancer and Ovarian/Cervical Cancer.
Important Safety Note: Ifosfamide metabolism produces the urotoxic metabolite Acrolein, which necessitates the mandatory co-administration of a uroprotectant agent like Mesna to prevent Hemorrhagic Cystitis. We ensure all partners are fully supported with educational and marketing materials detailing this crucial co-treatment protocol.
Partnering for the IFOSIDE 1GM PCD Pharma Franchise offers a chance to secure a monopoly in a highly specialized, recurring revenue segment of the oncology market, backed by WHO-GMP compliant quality and robust institutional demand.
May cause nausea, vomiting, fatigue, low blood counts, hair loss, and bladder irritation. Rarely, neurotoxicity, kidney toxicity, or severe infections may occur.
Soft tissue and bone sarcomas Lymphomas Testicular cancer Other solid tumors as per oncologist’s guidance
Administer only under strict medical supervision in a hospital or oncology setting. Blood counts, liver, kidney, and bladder function should be regularly monitored. Adequate hydration and protective agents may be required to prevent bladder toxicity. Report any neurological symptoms, unusual bleeding, or infections promptly.
Store below 25°C, protected from light. Keep out of reach of children. Use immediately after reconstitution as per medical instructions.
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : Rosuvastatin 10mg + Clopidogrel 75mg Capsule
Composition : Rosuvastatin 20mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
Composition : Aspirin 75mg + Rosuvastatin 20mg + Clopidogrel 150mg Tablet
Composition : Rosuvastatin 20 mg + Ezetimibe 10 mg tablet
Composition : Rosuvastatin 10 mg tablet
Composition : Rosuvastatin (20mg) tablet
Composition : Rosuvastatin 10 mg + fenofibrate 160 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Ifosfamide IP 1g Injection is an anti-cancer (alkylating agent) chemotherapy drug used in oncology protocols, making it a highly specialized hospital-only product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in oncology hospitals and cancer treatment centers. It is commonly used in the management of cancers such as sarcomas, lymphomas, and other solid tumors under strict specialist supervision, ensuring steady institutional demand.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Ifosfamide IP 1g Injection with monopoly rights, oncology-grade manufacturing standards, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from stable hospital procurement, long-term oncology treatment cycles, and high-value institutional sales when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this oncology formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.